56 results about "Bortezomib" patented technology

The invention provides an application of bortezomib in preparation of an anti-avian influenza virus drug. The bortezomib has the application of inhibiting the activity of avian influenza virus H7N9 neuraminidase. Researches show that the bortezomib can be combined with neuraminidase, the virtual calculation activity IC50 based on calculation is 3.37 * 10 <-7 > mol / L, the bortezomib can reduce the activity of neuraminidase, and the IC50 is 35.561 mu M; the bortezomib can inhibit the replication and propagation of avian influenza H7N9, and the IC50 is 0.043 [mu] M. In a word, the bortezomib has obvious activity of inhibiting neuraminidase of the avian influenza virus H7N9 and has the application of resisting the avian influenza virus.

The invention relates to the technical field of medicine preparation, and provides a bortezomib nano composition, and the bortezomib nano composition comprises the following components: bortezomib, albumin and a medium. The bortezomib nano composition can be delivered in a targeted manner, is low in toxicity and stable, and provides a new strategy for treatment of multiple myeloma.

The invention discloses an application of a small-molecule inhibitor combined medicine in preparation of a medicine for treating multiple myeloma. The application comprises the step of combining a proteasome inhibitor or an immunomodulator with an STAT3 small-molecule inhibitor. According to the present invention, the killing effect of the STAT3 targeting small molecule inhibitor BBI608 (Napabucasin) on MM cells and MM stem cells is provided, and the STAT3 targeting small molecule inhibitor BBI608 (Napabucasin) is combined with bortezomib (BTZ) or lenalidomide (Len) to improve the synergistic killing effect on multiple myeloma (MM) cells;

Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.

The invention relates to preparation and application of copper-sulfur group nano hydrogel. The research successfully synthesizes a copper-sulfur group nano-composite system with higher stability, the nano-system is utilized to perform experimental verification in vivo and in vitro, the application of the nano-system in the field of bladder cancer treatment is explored, a new strategy is provided for dealing with the limitation of current bladder cancer treatment, the Cu2-xSe (at) PDA (at) BTZ nano-material is prepared by utilizing a one-pot method, and the application of the nano-system in the bladder cancer treatment field is expanded. The surface of Cu2-xSe is modified through PDA, Cu2-xSe is wrapped in the PDA, bortezomib (BTZ) can be connected with the PDA through a phenylboronic acid ester bond, meanwhile, PDA of a coating layer of the composite material can be crosslinked with four-arm-polyethylene glycol-sulfydryl (4ARM-PEG-SH) to form nano hydrogel, the residence time of a medicine in the bladder can be prolonged through a copper-sulfur group nano-composite nano material, and the medicine can be applied to the bladder treatment. The contact time of the bladder mucosa and the medicine is prolonged, the medicine slow release effect is achieved, and efficient utilization of the medicine is achieved.

The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

The invention relates to the technical field of biological medicine, in particular to a nano antibody conjugate as well as a preparation method and application thereof. The nano antibody conjugate comprises coupled antibody fusion protein and bortezomib; the antibody fusion protein is a fusion protein of elastin-like polypeptide and an anti-Her2 nano antibody. The nanometer antibody conjugate can improve the stability and enzyme selectivity of bortezomib and reduce the toxic and side effects of drugs, meanwhile, the tumor targeting effect is achieved by combining a tumor specific nanometer antibody targeting technology, and the nanometer antibody conjugate can be used for treating Her2 high-expression cancers and has excellent application and popularization value and potential.

The invention provides an application of gastrodin in preparation of a medicine for treating peripheral neuropathy. According to the application disclosed by the invention, gastrodin can inhibit neuroinflammation mediated by microglia by inhibiting activation of an NF-kB / NLRP3 inflammasome signal channel, so that release of inflammatory factors is reduced, and neuropathy induced by bortezomib is relieved.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention relates to an iRGD modified dual drug-loading liposome and an application of the iRGD modified dual drug-loading liposome in radiotherapy sensitization of targeted glioblastoma. The liposome is composed of HSPC, CHO-HP, DSPE-mPEG2000, and DSPE-PEG2000-MAL, and is loaded with Osimertinib (Osimertinib) and Bortezomib (Bortezomib) through a pH (Potential of Hydrogen) gradient method, and the preparation method of the liposome comprises the following steps: carrying out a reaction on the Osimertinib (Osimertinib) and the Bortezomib (Bortezomib) in the presence of a Osimertinib is used as an EGFR inhibitor, bortezomib is used as a proteasome inhibitor, and osimertinib and bortezomib synergistically enhance the radiotherapy sensitivity by weakening the DNA repair capability of tumor cells. The iRGD peptide on the surface of the liposome is combined with tumor cell specific receptors alpha v beta 3 and NRP1 in a targeting manner, so that the liposome is mediated to pass through tumor neovascularization and efficiently deliver drugs to tumor parts. Animal experiment results show that the enrichment of the liposome in tumor tissues is obviously higher than that of common liposome, and the drug release has good controllability. Compared with the prior art, the invention has obvious advantages in tumor targeting, drug delivery efficiency and radiotherapy sensitization effect, is suitable for combined treatment of radiotherapy drug-resistant glioblastoma, and has a wide clinical application prospect.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The present invention relates to a pharmaceutical composition comprising mitogens and stress control pathway inhibitors for the treatment of cancer. The present invention more specifically relates to a pharmaceutical composition comprising FGF-2 and bortezomib or LB-100 and bortezomib for the treatment of cancer cells without compromising the survival of normal cells.

The present invention belongs to the technical field of drug carriers, and particularly relates to a nano-gel drug delivery system loaded with bortezomib and a preparation method thereof. The present invention uses a gelatin-dopamine (Gel-Dopa) complex and oxidized hyaluronic acid (OHA) as substrates to construct a nano-gel-based drug delivery system loaded with the chemotherapeutic drug BTZ. According to the characteristics of low pH in tumor tissues and overexpression of MMP-2 enzyme, a nano-gel with dual sensitivity to pH and MMP-2 enzyme is designed, and at the same time, the active targeting ability of HA is combined to improve the delivery efficiency of BTZ to tumor tissues, reduce the toxic and side effects of BTZ on normal cell tissues, and achieve controlled release of the drug.

This invention provides the application of the IFI16 gene as a target in the preparation of bortezomib-resistant drugs for the treatment of multiple myeloma, involving drug targets, related diagnostic reagents, and treatment strategies for the diagnosis and treatment of multiple myeloma (MM). This invention reveals for the first time the core driving role of IFI16 in bortezomib resistance in MM and its novel mechanism of action through the Wnt / β-catenin pathway; more importantly, it provides novel biomarkers, drug targets, and highly feasible combination therapy regimens for accurate prognostic assessment of MM and overcoming the clinically challenging problem of bortezomib resistance, possessing significant theoretical implications and broad clinical application prospects.

The invention belongs to the field of medical injection, and discloses a multi-section myeloma targeted therapy injection device which comprises a support, a lifting device fixedly arranged above the support, a clamping device fixedly arranged above the lifting device, a placing device fixedly arranged below the support, and a medicine bottle movably arranged in the placing device. An injection tube is movably arranged on one side of the lifting device and the clamping device, a push rod is movably arranged on the inner wall of the injection tube, a needle is embedded below the injection tube, and an adjusting device is arranged on the inner wall of the push rod in a threaded fit mode; the device solves the problems that when an existing targeted therapy device injects bortezomib, in the liquid medicine injection process, sectional injection is difficult to conduct on liquid medicine, injection amount precision control is poor during manual injection, and the therapeutic effect is affected, and is suitable for myeloma targeted therapy injection.

The invention discloses and provides an optimized process route for synthesizing a bortezomib intermediate, so that the reaction yield is greatly improved, the product purity is improved, continuous design is adopted in the process, the pollution is reduced, the yield is improved, and the cost is reduced.

This invention provides the application of indexsulfanilamide in the preparation of drugs for the prevention and / or treatment of multiple myeloma, belonging to the field of oncology drug technology. Indexsulfanilamide exhibits significant anti-multiple myeloma effects in various multiple myeloma cell lines, primary cells, and multiple myeloma mouse models, and inhibits tumor growth in multiple myeloma mice while demonstrating good safety. Furthermore, the combination of indexsulfanilamide and bortezomib produces a synergistic effect, suggesting that indexsulfanilamide has a promising therapeutic prospect for multiple myeloma.

The present invention relates to the field of biomedicine, and in particular to a nanobody conjugate, its preparation method, and application. The nanobody conjugate comprises a conjugated antibody fusion protein and bortezomib; the antibody fusion protein is a fusion protein of an elastin-like polypeptide and an anti-Her2 nanobody. The nanobody conjugate of the present invention can improve the stability and enzyme selectivity of bortezomib, reduce the drug's toxic side effects, and simultaneously achieve tumor targeting effects by combining tumor-specific nanobody targeting technology. It can be used to treat cancers with high Her2 expression, and has excellent value and potential for widespread application.

The invention relates to the technical field of medicines, in particular to a covalent organic framework material loaded with a boron drug compound as well as a preparation method and application of the covalent organic framework material. The covalent organic framework material loaded with the boron drug compound comprises bortezomib and a loading body, and the loading body is prepared from a covalent organic framework material modified by folic acid. The pore size regulation of the triazinyl COF is matched with the molecular size of the boron drug, and the topological structure design (AA stacking mode) of the COF is combined with the dynamic simulation of drug molecules, so that the ultrahigh drug loading capacity (42.7%) and the high retention rate gt of the drug within 72 hours are realized; moreover, folic acid molecules are connected through thioether bonds, so that gt is realized while the COF crystallinity is kept; and the FA surface coverage rate is 85%. The three-in-one design of'structure adaptive drug loading, chemical stable targeting and accurate environment release 'is realized for the first time, an efficient drug delivery platform is provided for advanced therapies such as boron neutron capture therapy (BNCT) and the like, and cross development of anti-cancer drugs from'extensive chemotherapy' to'molecular-level accurate regulation and control 'is promoted.

The invention discloses an application of a CaMKII-gamma inhibitor serving as a bortezomib-resistant multiple myeloma treatment medicine. On the basis of si-RNA, cell proliferation activity can be inhibited by down-regulating expression of CaMKII-gamma in bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, a small molecule compound rucotinib capable of effectively inhibiting activity of CaMKII-gamma kinase is obtained through high-throughput screening, growth of multiple myeloma U266 cells and KMS11 cells can be obviously inhibited, and the activity of the rucotinib can be effectively inhibited. The compound has an obvious inhibition effect on the growth of bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, also has an obvious inhibition effect on the growth of U266.BR transplantation tumors, and shows a good tumor inhibition effect as a potential medicine for treating multiple myeloma and bortezomib-resistant multiple myeloma.

The invention belongs to the field of biological medicines, and particularly relates to application of a compound to preparation of a medicine for treating papilloma of the upper respiratory tract. The invention provides an application of a compound in preparation of a medicine for treating and / or preventing papilloma of the upper respiratory tract, and is characterized in that the compound comprises one or more of asperisib, crizotinib, lapatinib, osimertinib and bortezomib. Experimental results show that the asperisib, crizotinib, lapatinib, osimertinib and bortezomib can realize long-term control on the papilloma of the upper respiratory tract and reduce the recurrence risk of the papilloma of the upper respiratory tract to a certain extent, so that the life quality of patients with the papilloma of the upper respiratory tract can be improved; the invention has important scientific value and clinical application prospect in the field of upper respiratory papilloma treatment.

Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenstrom's Macroglobulinaemia (WM), providing the rationale for investigating the combination.Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III / IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status ≥1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3 mg / m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375 mg / m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6 mg / m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375 mg / m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO 17:1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood 107:3442, 2006)Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm B. Haematological toxicity (grade≥3: anaemia 0%, neutropenia 25%, thrombocytopenia 22%) was significantly influenced by the high percentage of pts. with BM infiltration and concomitant cytopenia on entry to the trial. The most common non-haematological adverse events were fatigue (76%), nausea (56%), diarrhoea (56%), lethargy (46%). Neurotoxicity occurred in 19 pts. (46%) (10 pts. grade 1, 7 pts. grade 2, 2 pts. grade 3). Btz dose was reduced in 7 pts.; 5 doses were omitted because of neuro or haematological toxicity. In 16 pts., treatment was delayed by 1-14 days and in 24 pts. treatment was stopped prematurely. The reasons for stopping treatment were: treatment-related toxicity 11 pts., progressive disease 9 pts., patient's preference 3 pts., myocardial infarction 1 pt. One pt. was excluded having been found ineligible post randomisation. Thirty-nine pts. (21 arm A, 18 arm B) are evaluable for response so far, one having only received 1 cycle of therapy, which had to be discontinued because of excessive toxicity. 15 / 32 were in remission (CR, CRu, PR) at the completion of therapy, 7 / 7 at “mid-therapy” assessment, and 5 have yet to be evaluated. Thus the overall response rate (RR) presently is 22 / 39 (56%) (CR, CRu, PR), FL 44%, MCL 46%, WM 90%.Conclusions:The combination was active in pts. with recurrent NHL especially WM (RR 90%), despite multiple previous treatments, The weekly schedule is preferable being more convenient, as efficacious and no more toxic.Further investigation is warranted, despite not insignificant therapy compromising toxicity.

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and / or Ibrutinib.

The invention discloses a bortezomib and illicit loaded targeted copper / calcium bimetal-based nanocage and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out in-situ etching on amorphous calcium carbonate nanospheres by using a copper chloride aqueous solution to form the copper / calcium bimetal-based nanocage; the preparation method comprises the following steps: loading bortezomib and illicit in a nanocage under the coordination action to form a bortezomib and illicit loaded copper / calcium bimetal-based nanocage; and then carrying out surface modification by using hydrazide hyaluronic acid to form the bortezomib and illicit loaded targeted copper / calcium double-metal-based nanocage capable of specifically acting with cancer cells. The copper / calcium bimetal-based nanocage has the structural characteristics of large specific surface area, moderate particle size and pore size, capability of coordinating and combining a plurality of groups and the like, is high in drug loading capacity, and has pH / glutathione dual responsiveness and Fenton-like catalytic reaction characteristics. According to the invention, the bortezomib and the illicit are loaded in the nanocage through coordination, and the drug loading rates respectively reach 13.9% and 31.7%; the final nanocage has a tumor targeting function and can efficiently trigger cancer cell endoplasmic reticulum stress and nematode damage, and the synergistic amplification effect of the two can significantly enhance the immunotherapy effect.

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and / or Ibrutinib.

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

The invention belongs to the technical field of drug carriers, and particularly relates to a bortezomib encapsulating agent, a bortezomib liposome and a preparation method. The bortezomib encapsulating agent is liposome, the raw material components of the bortezomib encapsulating agent at least contain lipid with negative charges and cholesterol, and the bortezomib encapsulating agent can be prepared through a lipid dispersion method or a solvent injection method. According to the bortezomib liposome obtained by incubating the bortezomib encapsulating agent and bortezomib, the encapsulation efficiency can reach 80% or above, and the particle size is small and can reach about 100 nm.

This application provides a pharmaceutical composition and its application for treating liver cancer, relating to the field of biomedical technology. The pharmaceutical composition includes active ingredients, namely the proteasome inhibitor Bortezomib and the Rev-Erb agonist SR9009. By combining the proteasome inhibitor Bortezomib with the Rev-Erb agonist SR9009, synergistic anti-liver cancer activity is observed both in vitro and in vivo, enhancing the mechanism of protein toxicity-induced apoptosis in liver cancer cells. The combined effect of Bortezomib and Rev-Erb agonist SR9009 is significantly superior to either Bortezomib or Rev-Erb agonist alone, overcoming the poor efficacy of Bortezomib monotherapy in liver cancer, and demonstrating significant synergistic effects and clinical application value.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.